A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients With Embryonal and Alveolar Rhabdomyosarcoma
Phase of Trial: Phase I/II
Latest Information Update: 17 Jun 2019
Price : $35 *
At a glance
- Drugs Dasatinib (Primary) ; Ganitumab (Primary)
- Indications Rhabdomyosarcoma
- Focus Adverse reactions; Therapeutic Use
- 17 Apr 2019 Planned number of patients changed from 24 to 40.
- 04 Dec 2018 Planned primary completion date changed from 31 Oct 2021 to 1 Jan 2021.
- 31 Aug 2018 Biomarkers information updated